Elevated MIR100HG promotes colorectal cancer metastasis and is associated with poor prognosis.

mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG), which is located on chromosome 11q24.1, is a polycistronic microRNA host gene. MIR100HG overexpression in colorectal cancer (CRC) has been demonstrated to be associated with cetuximab resistance; however, the role of MIR100HG in CRC metastasis remains unclear. The present study aimed to investigate the impact of aberrant MIR100HG expression on metastasis and prognosis in patients with CRC. The results from reverse transcription-quantitative PCR demonstrated that MIR100HG expression was higher in CRC tissues compared with in corresponding normal mucosa tissues. In particular, MIR100HG expression was higher in advanced CRC compared with in early stage CRC. Furthermore, the results from Kaplan-Meier analysis followed by a log-rank test revealed that patients with CRC and high MIR100HG expression exhibited poorer disease-free survival and overall survival compared with patients with CRC and lower MIR100HG expression. Furthermore, results from in vitro Transwell assays and in vivo animal assays demonstrated that upregulated MIR100HG expression promoted CRC cell migration and invasion and the formation of liver metastatic colonies in mice. In conclusion, the present study demonstrated that MIR100HG overexpression may contribute to the progression of CRC and may predict a poorer prognosis in patients with CRC. MIR100HG may therefore be considered as a novel therapeutic target and a prognostic biomarker in patients with CRC.